Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Carter, Nick ^a   Pamba, Allan ^a   Duparc, Stephan ^b   Waitumbi, John N ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b International Center Cointrin   (Switzerland)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; CHLOROGUANIL, DAPSONE DRUG COMBINATION; DAPSONE; DRUG DERIVATIVE; PROGUANIL;

ADOLESCENT; AFRICA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENT TREPONEMA ANTIBODY TEST; GENOTYPE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMATOCRIT; HETEROZYGOTE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; PARASITEMIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REINFECTION; RETICULOCYTE HEMOGLOBIN CONTENT; SCHOOL CHILD; TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GENETICS; INFANT; PHASE 3 CLINICAL TRIAL; PHENOTYPE; TREATMENT OUTCOME;

ADOLESCENT; AFRICA; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DAPSONE; DRUG COMBINATIONS; FEMALE; GENOTYPE; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PHENOTYPE; PROGUANIL; TREATMENT OUTCOME;

EID: 80051610492     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-241     Document Type: Article

References (30)

1. Glucose-6-phosphate dehydrogenase deficiency. Luzzatto L, Mehta A, Vulliamy T, The Metabolic & Molecular Bases of Inherited Disease New York: McGraw Hill, Scriver C, Beaudet A, Sly W, Valle D, 2001 3 4517 4553 21936056
2. Hematologically important mutations: glucose-6-phosphate dehydrogenase. Beutler E, Vulliamy TJ, Blood Cells Mol Dis 2002 28 93 103 10.1006/bcmd.2002. 0490 12064901 (Pubitemid 34743740)
3. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, Richardson A, Teo YY, Small K, Wilson J, Jallow M, Sisay-Joof F, Pinder M, Sabeti P, Kwiatkowski DP, Rockett KA, Eur J Hum Genet 2009 17 1080 1085 10.1038/ejhg.2009.8 19223928
4. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, Gupta S, Warn P, Allsopp CE, Gilbert SC, Peschu N, Newbold C, Greenwood B, Marsh K, Hill A, Nature 1995 376 246 249 10.1038/376246a0 7617034
5. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA, PLoS Med 2007 4 66 10.1371/journal.pmed.0040066 17355169 (Pubitemid 46495319)
6. Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A-. Vulliamy TJ, Othman A, Town M, Nathwani A, Falusi AG, Mason PJ, Luzzatto L, Proc Natl Acad Sci USA 1991 88 8568 8571 10.1073/pnas.88.19.8568 1924316 (Pubitemid 21915398)
7. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Hirono A, Beutler E, Proc Natl Acad Sci USA 1988 85 3951 3954 10.1073/pnas.85.11.3951 2836867
8. The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal. De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, Ducrocq R, Haematologica 2006 91 262 263 16461316
9. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Beutler E, Duparc S, Am J Trop Med Hyg 2007 77 779 789 17978087 (Pubitemid 351844308)
10. Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. Tiono AB, Dicko A, Ndububa DA, Agbenyega T, Pitmang S, Awobusuyi J, Pamba A, Duparc S, Goh LE, Harrell E, Carter N, Ward SA, Greenwood B, Winstanley PA, Am J Trop Med Hyg 2009 81 969 978 10.4269/ajtmh.2009.09-0351 19996424
11. Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, Borrmann S, Sowunmi A, Duparc S, Kirby PL, Pamba A, Kellam L, Guiguemde R, Greenwood B, Ward SA, Winstanley PA, PLoS One 2009 4 6682 10.1371/journal.pone.0006682 19690618
12. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Luzzatto L, Lancet 376 739 741 doi:10.1016/S0140-6736 20599264
13. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JG, Lang T, Missinou MA, Mkandala C, Oduola AM, Premji Z, Robertson L, Sowunmi A, Ward SA, Winstanley PA, Lancet 2004 363 1843 1848 10.1016/S0140-6736(04)16350-2 15183620 (Pubitemid 38748637)
14. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50). World Health Organization, http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/
15. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G, Am J Trop Med Hyg 2003 68 133 139 12641400 (Pubitemid 38240534)
16. Methods and techniques for clinical trials on anti-malarial drug efficacy: genotyping to identify parasite populations. Medicines for Malaria Venture, World Health Organization, http://www.who.int/malaria/publications/ atoz/9789241596305/en/
17. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A. Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT, Blood 1989 74 2550 2555 2572288
18. At least five polymorphic mutants account for the prevalence of glucose-6-phosphate dehydrogenase deficiency in Algeria. Nafa K, Reghis A, Osmani N, Baghli L, Ait-Abbes H, Benabadji M, Kaplan JC, Vulliamy T, Luzzatto L, Hum Genet 1994 94 513 517 DOI: 10.1007/BF00211017 7959686 (Pubitemid 24340664)
19. Population study of common glucose-6-phosphate dehydrogenase mutations in Kuwait. Samilchuk E, D'Souza B, Al-Awadi S, Hum Hered 1999 49 41 44 DOI: 10.1159/000022838 9858856 (Pubitemid 29050294)
20. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Beutler E, Mitchell M, Blood 1968 32 816 818 4386875
21. Diagnosis of red cell G6PD deficiency in rural Burkina Faso: comparison of a rapid fluorescent enzyme test on filter paper with polymerase chain reaction based genotyping. Meissner PE, Coulibaly B, Mandi G, Mansmann U, Witte S, Schiek W, Muller O, Schirmer RH, Mockenhaupt FP, Bienzle U, Br J Haematol 2005 131 395 399 10.1111/j.1365-2141.2005.05778.x 16225660 (Pubitemid 43899672)
22. Relationship between the genes for glucose-6-phosphate dehydrogenase and for haemoglobin in a Nigerian population. Luzzatto L, Allan NC, Nature 1968 219 1041 1042 10.1038/2191041a0 5673357
23. Red cell glucose-6-phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population. May J, Meyer CG, Grossterlinden L, Ademowo OG, Mockenhaupt FP, Olumese PE, Falusi AG, Luzzatto L, Bienzle U, Trop Med Int Health 2000 5 119 123 10.1046/j.1365-3156.2000.00529.x 10747271 (Pubitemid 30159129)
24. Molecular epidemiology and activity of erythrocyte G6PD variants in a homogeneous Nigerian population. Ademowo OG, Falusi AG, East Afr Med J 2002 79 42 44 http://www.ajol.info/index.php/eamj/article/viewFile/8924/1751 12380870
25. Spleen size determined by ultrasound in patients with sickle cell trait, HbAC trait and glucose-6-phosphate-dehydrogenase deficiency in a malaria hyperendemic area (Ashanti Region, Ghana). Burchard GD, Browne EN, Sievertsen J, May J, Meyer CG, Acta Trop 2001 80 103 109 10.1016/S0001-706X(01)00157-7 11600086 (Pubitemid 32964766)
26. Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan. Chien YH, Lee NC, Wu ST, Liou JJ, Chen HC, Hwu WL, Southeast Asian J Trop Med Public Health 2008 39 154 161 http://www.tm.mahidol.ac.th/seameo/2008-39-1/21-4176.pdf 18567456
27. Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. Johnson MK, Clark TD, Njama-Meya D, Rosenthal PJ, Parikh S, PLoS One 2009 4 7246 10.1371/journal.pone.0007246 19789650
28. Reduced risk of uncomplicated malaria episodes in children with alpha+-thalassemia in northeastern Tanzania. Enevold A, Lusingu JP, Mmbando B, Alifrangis M, Lemnge MM, Bygbjerg IC, Theander TG, Vestergaard LS, Am J Trop Med Hyg 2008 78 714 720 18458302 (Pubitemid 351845125)
29. Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali. Kone AK, Sagara I, Thera MA, Dicko A, Guindo A, Diakite S, Kurantsin-Mills J, Djimde A, Walcourt A, Doumbo O, Malar J 9 332 doi:10.1186/1475-2875-9-332 21092137
30. Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants. Vafa M, Troye-Blomberg M, Anchang J, Garcia A, Migot-Nabias F, Malar J 2008 7 17 10.1186/1475-2875-7-17 18215251 (Pubitemid 351378200)